Table 5 Treatment efficacy and prognosis of KRAS mutant NSCLC treated with different chemotherapy scheme

Treatment scheme

ORR

OR (95%CI)

P value

DCR

OR (95%CI)

P value

 TAX+AT group

59.09%

–

–

95.45%

–

–

 PEM + AT group

30.56%

3.283 (1.085–9.930)

0.032

91.67%

1.909 (0.186–19.589)

0.985

 PEM (no-AT) group

12.50%

10.111 (2.305–44.348)

0.001

66.67%

10.500 (1.189–92.727)

0.037

 TAX (no-AT) group

26.92%

3.921 (1.165–13.198)

0.024

73.08%

7.737 (0.870–68.803)

0.092

Median PFS(95%CI)(month)

HR (95%CI)

P value

Median OS(95%CI)(month)

HR (95%CI)

P value

 PEM + AT group

14.0 (9.9–18.1)

–

–

25.0 (5.7–44.3)

–

–

 PEM (no-AT) group

4.0 (2.6–5.4)

0.487 (0.264–0.900)

0.009

10.0 (3.5–16.5)

0.419 (0.214–0.822)

0.006

 TAX+AT group

8.0 (5.4–10.6)

0.474 (0.253–0.889)

0.008

19.0 (13.3–24.7)

0.793 (0.385–1.594)

0.508

 TAX (no-AT) group

5.0 (3.7–6.3)

0.303 (0.153–0.601)

< 0.001

11.0 (6.11–15.9)

0.336 (0.174–0.648)

< 0.001